Azacitidine Kabi

Azacitidine Kabi is used for the treatment of adults with the following diseases if they cannot have haematopoietic stem cell transplantation (when the patient receives stem cells to restore the bone marrow’s ability to produce healthy blood cells): - myelodysplastic syndromes, a group of conditions where the bone marrow produces abnormal blood cells and not enough healthy ones. In some cases, myelodysplastic syndromes can lead to acute myeloid leukaemia (AML, a cancer affecting white blood cells called myeloid cells). Azacitidine Kabi is used in patients with an intermediate to high risk of progressing to AML or death; - chronic myelomonocytic leukaemia (a cancer affecting white blood cells called monocytes). Azacitidine Kabi is used when the bone marrow consists of 10 to 29% abnormal cells and the bone marrow is not producing large numbers of white blood cells; - AML that has developed from a myelodysplastic syndrome, where the bone marrow consists of 20 to 30% abnormal cells; - AML, where the bone marrow has more than 30% abnormal cells. Azacitidine Kabi is a ‘generic medicine’. This means that Azacitidine Kabi contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Azacitidine Kabi is Vidaza. Azacitidine Kabi contains the active substance azacitidine.